X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA DR. REDDYS LAB SHASUN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 123.9 29.9 414.3% View Chart
P/BV x 8.5 2.9 291.1% View Chart
Dividend Yield % 0.2 0.9 25.3%  

Financials

 SHASUN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
DR. REDDYS LAB
Mar-17
SHASUN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs943,397 2.8%   
Low Rs462,560 1.8%   
Sales per share (Unadj.) Rs214.2856.5 25.0%  
Earnings per share (Unadj.) Rs5.378.0 6.8%  
Cash flow per share (Unadj.) Rs15.8139.9 11.3%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %1.40.7 213.0%  
Book value per share (Unadj.) Rs53.3739.8 7.2%  
Shares outstanding (eoy) m56.62165.74 34.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.33.5 9.4%   
Avg P/E ratio x13.138.2 34.3%  
P/CF ratio (eoy) x4.421.3 20.8%  
Price / Book Value ratio x1.34.0 32.6%  
Dividend payout %18.725.7 73.1%   
Avg Mkt Cap Rs m3,958493,632 0.8%   
No. of employees `000NA22.7 0.0%   
Total wages/salary Rs m2,16431,068 7.0%   
Avg. sales/employee Rs ThNM6,259.0-  
Avg. wages/employee Rs ThNM1,369.8-  
Avg. net profit/employee Rs ThNM569.7-  
INCOME DATA
Net Sales Rs m12,127141,961 8.5%  
Other income Rs m2291,715 13.4%   
Total revenues Rs m12,356143,676 8.6%   
Gross profit Rs m1,00924,722 4.1%  
Depreciation Rs m59410,266 5.8%   
Interest Rs m415634 65.5%   
Profit before tax Rs m23015,537 1.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 -0.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-732,965 -2.5%   
Profit after tax Rs m30212,921 2.3%  
Gross profit margin %8.317.4 47.8%  
Effective tax rate %-31.719.1 -165.9%   
Net profit margin %2.59.1 27.4%  
BALANCE SHEET DATA
Current assets Rs m6,88496,837 7.1%   
Current liabilities Rs m8,45684,199 10.0%   
Net working cap to sales %-13.08.9 -145.6%  
Current ratio x0.81.2 70.8%  
Inventory Days Days6273 84.0%  
Debtors Days Days10898 110.1%  
Net fixed assets Rs m4,970102,552 4.8%   
Share capital Rs m113829 13.7%   
"Free" reserves Rs m2,875121,792 2.4%   
Net worth Rs m3,020122,621 2.5%   
Long term debt Rs m1,8175,449 33.4%   
Total assets Rs m13,347218,165 6.1%  
Interest coverage x1.625.5 6.1%   
Debt to equity ratio x0.60 1,354.1%  
Sales to assets ratio x0.90.7 139.6%   
Return on assets %5.46.2 86.5%  
Return on equity %10.010.5 94.9%  
Return on capital %13.312.9 103.3%  
Exports to sales %46.454.6 84.9%   
Imports to sales %14.29.4 152.4%   
Exports (fob) Rs m5,62277,520 7.3%   
Imports (cif) Rs m1,72813,274 13.0%   
Fx inflow Rs m5,84381,670 7.2%   
Fx outflow Rs m2,17326,355 8.2%   
Net fx Rs m3,66955,315 6.6%   
CASH FLOW
From Operations Rs m39821,444 1.9%  
From Investments Rs m-1,635-18,404 8.9%  
From Financial Activity Rs m1,309-3,692 -35.4%  
Net Cashflow Rs m71-1,144 -6.2%  

Share Holding

Indian Promoters % 39.2 25.5 153.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 5.4 66.7%  
FIIs % 17.6 35.3 49.9%  
ADR/GDR % 0.0 18.5 -  
Free float % 39.6 15.3 258.8%  
Shareholders   20,750 75,885 27.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS